Home » Newsletters » BioWorld Science

BioWorld Science

April 10, 2008

View Archived Issues

Nestle sells 25% minority stake in Alcon to Novartis

Similar cardiac event rates in diabetics, non-diabetics given TAXUS Express stent

PROTECT study shows improved dyspnea, preserved renal function with rolofylline

Pilot study shows potential of beraprost in pulmonary arterial hypertension

Galderma completes an all cash tender offer for CollaGenex

Stable disease noted in prostate cancer patients treated with TroVax

GW reports preliminary phase III Sativex results in MS neuropathic pain

MAP reports positive phase IIa results for combination therapy in asthmatic adults

MediciNova reports results from two-year phase II MN-166 trial in MS

TaiGen presents positive data from phase II nemonoxacin study

Epix expands collaboration agreement with Cystic Fibrosis Foundation Therapeutics

Hemispherx accelerates Ampligen as an adjuvant for avian influenza and HIV vaccines

GW-406381 effective in phase II acute migraine study

Endo withdraws sNDA for Frova in menstrual migraine and returns rights to Chronogesic

Targeted Genetics acquires full exclusive rights to HD program from Sirna Therapeutics

Microbia changes name to Ironwood Pharmaceuticals

Biovitrum reports promising results from phase II study of BVT-115959 in neuropathic pain

Bristol-Myers Squibb selects Isis antisense drug targeting PCSK9 as development candidate

Anesiva initiates phase III clinical trial of Adlea in postsurgical pain following knee surgery

Arena initiates screening in phase IIb clinical trial of APD-125 in primary insomnia

Protox initiates phase II PRX-302 study in benign prostatic hyperplasia

Novel antiviral compounds disclosed in recent Coley patent

Wex commences phase III Tectin trial for cancer pain

Recent Ranbaxy patent reports novel therapeutic agents for urinary incontinence

New therapeutic agents for respiratory disorders described in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...